Ross Muken
Stock Analyst at Evercore ISI Group
(2.17)
# 2,584
Out of 4,767 analysts
44
Total ratings
57.14%
Success rate
2.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CRL Charles River Laboratories International | Maintains: In-Line | $190 → $225 | $171.04 | +31.55% | 6 | Nov 7, 2024 | |
PDCO Patterson Companies | Maintains: In-Line | $23 → $22 | $31.14 | -29.35% | 4 | Oct 8, 2024 | |
ICLR ICON Public Limited Company | Maintains: Outperform | $360 → $350 | $184.58 | +89.62% | 7 | Oct 8, 2024 | |
HSIC Henry Schein | Maintains: In-Line | $70 → $74 | $70.58 | +4.85% | 8 | Oct 8, 2024 | |
A Agilent Technologies | Maintains: In-Line | $126 → $130 | $121.18 | +7.28% | 11 | Jul 2, 2024 | |
QGEN Qiagen | Downgrades: In-Line | n/a | $39.48 | - | 2 | Jul 16, 2019 | |
CAH Cardinal Health | Initiates: In-Line | $67 | $128.00 | -47.66% | 2 | Jan 5, 2018 | |
ILMN Illumina | Initiates: Outperform | $250 | $85.60 | +192.06% | 2 | Jan 4, 2018 | |
TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $522.05 | -57.86% | 1 | Jan 4, 2018 | |
MBLY Mobileye Global | Downgrades: In-Line | n/a | $14.97 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Nov 7, 2024
Maintains: In-Line
Price Target: $190 → $225
Current: $171.04
Upside: +31.55%
Patterson Companies
Oct 8, 2024
Maintains: In-Line
Price Target: $23 → $22
Current: $31.14
Upside: -29.35%
ICON Public Limited Company
Oct 8, 2024
Maintains: Outperform
Price Target: $360 → $350
Current: $184.58
Upside: +89.62%
Henry Schein
Oct 8, 2024
Maintains: In-Line
Price Target: $70 → $74
Current: $70.58
Upside: +4.85%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $121.18
Upside: +7.28%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $39.48
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $128.00
Upside: -47.66%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $85.60
Upside: +192.06%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $522.05
Upside: -57.86%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $14.97
Upside: -